Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Drug Updates

  |  Issue: January 2009  |  

Michele Kaufman is a freelance medical writer based in New York City.

References

  1. Harper CR, Jacobson TA. The broad spectrum of statin myopathy: From myalgia to rhabdomyolysis. Curr Opin Lipidol. 2007; 18:401-408.
  2. Koumis T, Nathan JP, Rosenberg JM, Cicero LA. Strategies for the prevention and treatment of statin-induced myopathy: Is there a role for ubiquinone supplementation. Am J Health-Syst Pharm. 2004; 61:515-519.
  3. Pasternak RC, Smith C Jr, Bairney-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Stroke. 2002;33:2337-2341.
  4. Antons KA, Williams CD, Baker SK, Phillips PS. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med. 2006;119:400-409.
  5. Law M, Rudnicka AR. Statin Safety: A systematic review. Am J Cardiol. 2006;97(Suppl):52C-60C.
  6. Slim H, Thompson PD. Ezetimibe-related myopathy: A Systematic review. J Clin Lipidol. 2008;2:328-334.
  7. Christopher-Stine L. Stain myopathy: An update. Curr Opin Rhematol. 2006;16:647-653.
  8. Evans M, Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle – Are all statins the same? Drug Safety. 2002;25:649-663.
  9. Klopstock T. Drug-induced myopathies. Curr Opin Neurol. 2008;21:590-595.
  10. McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006;97(suppl):89C-94C.
  11. Link E for the SEARCH Collaborative Group. SCLO1B1 variants and statin-induced myopathy – A genomewide study. N Engl J Med. 2008;359:789-799.
  12. UCB files for R.: www.ucb-group.com/news/3019.asp. Last accessed October 20, 2008.
  13. FDA approves Cimzia to treat Crohn’s disease. www.fda.gov/bbs/topics/NEWS/2008/NEW01821.html. Last accessed October 20, 2008.
  14. EULAR RAPID results: www.medicalnewstoday.com/articles/111632.php Last accessed October 20, 2008.
  15. Additional RA indications/RA in Europe: http://hugin.info/133973/R/1239755/265632.pdf Last accessed October 20, 2008.
  16. BLA submitted for Golimumab. www.drugs.com/nda/golimumab_080627.html. Last accessed October 20, 2008.
  17. Drug Watch. Adult and juvenile rheumatoid arthritis drugs in development. Formulary. 2008;43:260.
  18. FDA issues complete response letter to Roche for ACTEMRA (tocilizumab) biologics license application. www.rocheusa.com/newsroom/current/2008/pr2008091801.html. Last accessed November 4, 2008.
  19. Important drug warning new safety information. www.fda.gov/medwatch/safety/2008/rituxan_DHCP_Final%209411700.pdf. Last accessed October 20, 2008.
  20. Prescribing information. www.fda.gov/medwatch/safety/2008/Rituxan_PI.pdf. Last accessed October 20, 2008.
  21. FDA: manufacturers of TNF-blocker drugs must highlight risk of fungal infections. www.fda.gov/bbs/topics/NEWS/2008/NEW01879.html. Last accessed October 20, 2008.
  22. Information for healthcare professionals Cimzia (certolizumab pegol), Enbrel (etanercept), Humira (adalimumab), and Remicade (infliximab) www.fda.gov/cder/drug/InfoSheets/HCP/TNF_blockersHCP.htm. Last accessed October 20, 2008.
  23. FDA approves updated labeling for psoriasis drug Raptiva. www.fda.gov/bbs/topics/NEWS/2008/NEW01905.html. Last accessed October 21, 2008.
  24. Prescribing information. www.gene.com/gene/products/information/pdf/raptiva-prescribing.pdf. Last accessed October 21, 2008.
  25. Important safety information. www.gene.com/gene/products/information/pdf/raptiva_dhcp.pdf. Last Accessed accessed October 21, 2008.

Related Articles

    Fellows’ Forum Case Report: Necrotizing Autoimmune Myopathy

    Necrotizing autoimmune myopathy (NAM) is a relatively recently discovered subgroup of inflammatory myopathies. NAM is characterized by predominant muscle fiber necrosis and regeneration with little or no inflammation.1 One subgroup of NAM is 3-hydroxy-3-methylglutaryl-CoA reductase antibody (HMGCR Ab)-related immune-mediated necrotizing myopathy (IMNM), which occurs (rarely) after statin exposure, with a rough incidence of two per…

    Case Report: What’s Causing This Severe Case of Rhabdomyolysis?

    Rhabdomyolysis is a clinical syndrome characterized by muscle tissue necrosis and release of intramuscular components into the circulation. Typical manifestations include muscle pain and myoglobinuria, causing dark urine. Serum creatinine kinase (CK) enzyme levels are usually markedly elevated. Severity can range from muscle enzyme elevation in the serum of an otherwise asymptomatic patient to extremely…

    AJPhoto / Science Source

    Tips for Diagnosing Metabolic Myopathies

    When evaluating patients with possible myopathic symptoms, rheumatologists must consider a rare, but important, group of inherited disorders: the metabolic myopathies. However, their diagnosis often remains a challenge. Early recognition of these primary metabolic myopathies is essential to help prevent disease morbidity and mortality from rhabdomyolysis. Here, we focus on the metabolic myopathies that present…